Evidence map›Paper›PMID 34055984›Full record

ArticleBioMed research international2021

Gold Nanoparticle-Bioconjugated Aminoguanidine Inhibits Glycation Reaction: An

Saheem Ahmad, Mohd Sajid Khan, Sultan Alouffi, Saif Khan, Mahvish Khan, Rihab Akashah, Mohammad Faisal, Uzma Shahab

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Could nanotechnology improve exercise performance? Evidence from animal studies.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Saheem AhmadDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Saudi Arabia.ORCID https://orcid.org/0000-0003-1215-0279
Mohd Sajid KhanDepartment of Biosciences, Integral University, Lucknow, India.
Sultan AlouffiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Saudi Arabia.ORCID https://orcid.org/0000-0003-3443-9700
Saif KhanDepartment of Basic Dental and Medical Sciences, College of Dentistry, University of Hail, Ha'il 2440, Saudi Arabia.
Mahvish KhanDepartment of Biology, College of Science, University of Hail, Ha'il 2440, Saudi Arabia.
Rihab AkashahDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Saudi Arabia.
Mohammad FaisalDepartment of Botany and Microbiology, College of Science, King Saud University, Saudi Arabia.ORCID https://orcid.org/0000-0002-8176-1527
Uzma ShahabDepartment of Biotechnology, Khwaja Moinuddin Chishti Language University, Sitapur-Hardoi Bypass Road, Lucknow 226013, India.ORCID https://orcid.org/0000-0003-1831-0069
University of Ha'il · SAAligarh Muslim University · INKing Saud University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteins undergo glycation resulting in the generation of advanced glycation end products (AGEs) that play a central role in the onset and advancement of diabetes-associated secondary complications. Aminoguanidine (AG) acts as an antiglycating agent by inhibiting AGE generation by blocking reactive carbonyl species (RCS) like, methylglyoxal (MGO). Previous studies on antiglycating behavior of AG gave promising results in the treatment of diabetes-associated microvascular complications, but it was discontinued as it was found to be toxic at high concentrations (>10 mmol/L). The current article aims at glycation inhibition by conjugating gold nanoparticles (Gnp) with less concentration of AG (0.5-1.0 mmol/L). The HPLC results showed that AG-Gnp fairly hampers the formation of glycation adducts. Moreover, the

Indexed as

AnimalsBlood GlucoseDiabetes ComplicationsDiabetes Mellitus, ExperimentalDisease Models, AnimalGlycation End Products, AdvancedGlycosylationGoldGuanidinesLysineMaleMetal NanoparticlesProteinsPyruvaldehydeRatsRats, WistarBlood GlucoseGlycation End Products, AdvancedGoldGuanidinesLysineN(6)-carboxymethyllysinepimagedineProteinsPyruvaldehyde

Identifiers

PMID34055984
PMCPMC8137289
OpenAlexW3161956488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.